Metabolic Imaging in Cardio-oncology

Dan Tong, Vlad G. Zaha

Research output: Contribution to journalReview article

Abstract

Tremendous progress in cancer detection and therapy has improved survival. However, cardiovascular complications are a major source of morbidity in cancer survivors. Cardiotoxicity is currently defined by structural myocardial changes and cardiac injury biomarkers. In many instances, such changes are late and irreversible. Therefore, diagnostic modalities that can identify early alterations in potentially reversible biochemical and molecular signaling processes are of interest. This review is focused on emerging translational metabolic imaging modalities. We present in context relevant mitochondrial biology aspects that ground the development and application of these technologies for detection of cancer therapy–related cardiac dysfunction (CTRCD). The application of these modalities may improve the assessment of cardiovascular risk when anticancer treatments with a defined cardiometabolic toxic mechanism are to be used. Also, they may serve as screening tools for cardiotoxicity when novel lines of cancer therapies are applied.

Original languageEnglish (US)
JournalJournal of Cardiovascular Translational Research
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Neoplasms
Heart Neoplasms
Poisons
Survivors
Therapeutics
Biomarkers
Technology
Morbidity
Survival
Wounds and Injuries
Cardiotoxicity

Keywords

  • Cancer
  • Cardio-toxicity
  • Chemotherapy
  • Metabolism

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmaceutical Science
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Cite this

Metabolic Imaging in Cardio-oncology. / Tong, Dan; Zaha, Vlad G.

In: Journal of Cardiovascular Translational Research, 01.01.2019.

Research output: Contribution to journalReview article

@article{01c16587fb9240bc8058f48c9e96a016,
title = "Metabolic Imaging in Cardio-oncology",
abstract = "Tremendous progress in cancer detection and therapy has improved survival. However, cardiovascular complications are a major source of morbidity in cancer survivors. Cardiotoxicity is currently defined by structural myocardial changes and cardiac injury biomarkers. In many instances, such changes are late and irreversible. Therefore, diagnostic modalities that can identify early alterations in potentially reversible biochemical and molecular signaling processes are of interest. This review is focused on emerging translational metabolic imaging modalities. We present in context relevant mitochondrial biology aspects that ground the development and application of these technologies for detection of cancer therapy–related cardiac dysfunction (CTRCD). The application of these modalities may improve the assessment of cardiovascular risk when anticancer treatments with a defined cardiometabolic toxic mechanism are to be used. Also, they may serve as screening tools for cardiotoxicity when novel lines of cancer therapies are applied.",
keywords = "Cancer, Cardio-toxicity, Chemotherapy, Metabolism",
author = "Dan Tong and Zaha, {Vlad G.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12265-019-09927-9",
language = "English (US)",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",

}

TY - JOUR

T1 - Metabolic Imaging in Cardio-oncology

AU - Tong, Dan

AU - Zaha, Vlad G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Tremendous progress in cancer detection and therapy has improved survival. However, cardiovascular complications are a major source of morbidity in cancer survivors. Cardiotoxicity is currently defined by structural myocardial changes and cardiac injury biomarkers. In many instances, such changes are late and irreversible. Therefore, diagnostic modalities that can identify early alterations in potentially reversible biochemical and molecular signaling processes are of interest. This review is focused on emerging translational metabolic imaging modalities. We present in context relevant mitochondrial biology aspects that ground the development and application of these technologies for detection of cancer therapy–related cardiac dysfunction (CTRCD). The application of these modalities may improve the assessment of cardiovascular risk when anticancer treatments with a defined cardiometabolic toxic mechanism are to be used. Also, they may serve as screening tools for cardiotoxicity when novel lines of cancer therapies are applied.

AB - Tremendous progress in cancer detection and therapy has improved survival. However, cardiovascular complications are a major source of morbidity in cancer survivors. Cardiotoxicity is currently defined by structural myocardial changes and cardiac injury biomarkers. In many instances, such changes are late and irreversible. Therefore, diagnostic modalities that can identify early alterations in potentially reversible biochemical and molecular signaling processes are of interest. This review is focused on emerging translational metabolic imaging modalities. We present in context relevant mitochondrial biology aspects that ground the development and application of these technologies for detection of cancer therapy–related cardiac dysfunction (CTRCD). The application of these modalities may improve the assessment of cardiovascular risk when anticancer treatments with a defined cardiometabolic toxic mechanism are to be used. Also, they may serve as screening tools for cardiotoxicity when novel lines of cancer therapies are applied.

KW - Cancer

KW - Cardio-toxicity

KW - Chemotherapy

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=85074863244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074863244&partnerID=8YFLogxK

U2 - 10.1007/s12265-019-09927-9

DO - 10.1007/s12265-019-09927-9

M3 - Review article

C2 - 31696405

AN - SCOPUS:85074863244

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

ER -